L2B - Brain cancer
Your external Innovation management to fight brain cancer
Unique combination of scientific, business and patient expertise on GBM and other brain tumors
Service eligible for the French government's tax credit “Credit d'Impot Recherche (CIR)”
I provide innovation management (R&D and BD) services to:
-
Develop preclinical research plans and manage R&D (See L2B-preclinical services Here) with in depth pharmacological expertise on brain tumors.
-
Help you explore Blood Brain Barrier (BBB) opening and crossing options.
-
Challenge your plans to increase your technology potential for brain tumors patients.
-
Conduct market research: competitive intelligence, product market fit, competitive advantage.
-
Reach out for partners among my extended and active network in the field.
-
Support medical writing and corporate/charity communication activities.
Recent project exemples:
-
Program Expert – clinical stage oncology molecule repositioning on GBM and modification for BBB crossing.
-
Project co-lead - efficacy and administration route optimization for a GBM targeting peptide.
-
Project lead: complete market study and startup development plan design for a brain cancer diagnostic solution to switch from a technology push to a demand pull with successful VC traction.
-
Scientific board member for 2 GBM related project, including the patient association DEDLM.
My unique value : from Scientist trough caregiver to contributor
One of the rare neuro-oncology preclinical PhD with 10+ years hands-on experience having both:
-
business mindset: with a master from HEC Paris and 3 experiences as C-level executive in the brain tumor era,
-
a patient’s relative experience, bonding with other patients’ families and association to fully understands the clinical practice beyond survival median time.
As a scientist I care about data, embracing complexity.
As a caregiver I integrate subtle emotions, intuition and hope.
As a business woman I’m on a mission to support, accelerate and increase the impact of your solution against brain Cancers by integrating my unique diverse experience.
Our Clients Say
" We called on Sandrine to establish the positioning of a neuroscience drug candidate for brain cancer indications. Sandrine demonstrated a rare ability to get involved quickly and independently in complex projects, which saved us time. She brought cutting-edge expertise in preclinical oncology, mobilized a powerful active network and shared significant ideas that were subsequently confirmed by KoL. The collaboration was fluid, with clear, rapid deliverables and a pleasant team spirit.
In 3 months, we achieved a clear positioning with a strategic vision and a competitive advantage that would have taken much longer without Sandrine.
Most importantly, Sandrine's insights, positive energy and management tools have nourished our global thinking and practices, leaving a lasting positive impact on our scientific and corporate strategy, well beyond the initial objective. "
Xenia Proton de la Chapelle, CEO & Nathan Beckouche CSO, AtmosR, France
Get in Touch
Let's discuss your needs.